Delivery Order SPE2DB24D2013-SPE2DB25FCJWR
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract is not set aside for any socioeconomic category and is scheduled for completion by August 12, 2025. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment...
- The Defense Logistics Agency awarded a $11,717.95 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price, competitively awarded contract has an ultimate completion date of September 10, 2025, and will be performed at the company's corporate office in Conshohocken, Pennsylvania. Tezspire is a biologic medication used to treat moderate-to-severe asthma, representing the type of specialized pharmaceutical product critical to military...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors on July 31, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 21, 2025, with performance taking place at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on August 11, 2025, with completion targeted for September 2, 2025. This is a non-set-aside, competitively awarded contract under which AmerisourceBergen will deliver the specified pharmaceutical product to support federal medical supply needs. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 for Tezspire 210 mg/1.91 mL pen injectors, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of high-value...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJWRDelivery Order
The Defense Logistics Agency awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors, with an ultimate completion date of September 3, 2025. This is a non-set-aside competitive award issued on August 12, 2025, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. Tezspire is a biologic medication used for moderate-to-severe asthma treatment, and this procurement supports the military healthcare supply chain requirements managed by the Defense Health Agency and other federal healthcare systems. AmerisourceBergen, as one of the nation's largest pharmaceutical distributors, regularly fulfills federal medical procurement needs through competitive delivery orders under its DLA prime vendor contract. The company's extensive portfolio with the Defense Logistics Agency demonstrates its established capability to supply brand-name pharmaceuticals, specialty medications, and medical devices across multiple therapeutic domains to support military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/12/25 |